Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advanced Glycation End-Products and Its Receptors in Cancer Progression
share announcement

Advanced Glycation End-Products and Its Receptors in Cancer Progression

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 703

Special Issue Editor

Dr. Bhaumik B. Patel

E-Mail Website
Guest Editor
Department of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA 23284, USA
Interests: advanced glycation end products; toxic advanced glycation end products; receptor for advanced glycation end products (RAGEs); glycosaminoglycans; cancer; cancer stem cells (CSCs); tumor immune microenvironment (TME)

Special Issue Information

Dear Colleagues,

Advanced glycation end products (AGEs) are a group of compounds formed when sugars react with proteins and lipids in the body. They have been implicated in various diseases, including cancer, through receptors for AGE (RAGEs), as well as dependent and independent mechanisms. An increasing body of literature implicates AGEs/RAGEs in various hallmarks of cancer, including the tumor immune microenvironment (TME), inflammation and cancer stem cells (CSCs). 

In this Special Issue, we aim to explore the latest research findings and advancements in understanding the role of AGEs in cancer. The issue will focus on the biochemistry and clinical detection of AGEs, their clinical relevance and biology, and the molecular mechanism of AGE/RAGE-induced carcinogenesis or therapeutic strategies targeting AGEs/RAGEs in cancer. We especially invite articles examining the role of glycosaminoglycans (GAGs) in regulating AGEs/RAGEs in cancer, as well as CSC biology and the role of AGEs/RAGEs in inflammatory TME and therapeutic targeting thereof. 

Dr. Bhaumik B. Patel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • advanced glycation end products
  • toxic advanced glycation end products
  • receptor for advanced glycation end products (RAGEs)
  • glycosaminoglycans
  • cancer
  • cancer stem cells (CSCs)
  • tumor immune microenvironment (TME)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

11 pages, 1659 KiB  
Perspective
Perspective on Immunoglobulin N-Glycosylation Status in Follicular Lymphoma: Uncovering BCR-Dependent and Independent Mechanisms Driving Subclonal Evolution
by Gloria Pokuaa Manu, Mariette Odabashian and Sergey Krysov
Cancers 2025, 17(7), 1219; https://doi.org/10.3390/cancers17071219 - 4 Apr 2025
Viewed by 392
Abstract
Follicular lymphoma (FL) is a heterogeneous and incurable disease. One of the hallmark features of FL cells is the introduction of N-glycosylation (N-gly) amino acid sequence motifs into the immunoglobulin variable (IgV) region through ongoing somatic hypermutation (SHM) in the early stages of [...] Read more.
Follicular lymphoma (FL) is a heterogeneous and incurable disease. One of the hallmark features of FL cells is the introduction of N-glycosylation (N-gly) amino acid sequence motifs into the immunoglobulin variable (IgV) region through ongoing somatic hypermutation (SHM) in the early stages of lymphoma development. These N-gly motifs, containing oligomannoses, are rarely found in healthy B cells but evidently play a crucial role in the clonal evolution and survival of FL cells in the hostile environment of germinal centers. The random nature of the ongoing SHM in FL occasionally results in the loss of productive immunoglobulin (Ig) genes or the elimination of N-gly motifs in productive genes. Such events typically lead to clonal deletion, as demonstrated by the longitudinal analysis of FL samples. However, rare N-gly-negative subclones demonstrate prolonged survival with evidence of ongoing SHM, giving rise to new N-gly-negative subclones before eventual deletion. This observation suggests the presence of specific mechanisms supporting their survival and proliferation. This perspective examines the current literature and explores whether a detailed transcriptomic and functional comparison of FL subclones characterized by different N-gly statuses, with a particular focus on N-gly-negative subclones, will lead to a comprehensive understanding of both N-gly-dependent and independent pro-survival and proliferative transcriptional signatures. Specifically, it aims to deepen our understanding of FL pathobiology and identify novel therapeutic targets for better disease management. Full article
(This article belongs to the Special Issue Advanced Glycation End-Products and Its Receptors in Cancer Progression)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop